The aim of the present review was to assess the prognostic impact of lymphovascular invasion (LVI) in transurethral resection (TUR) of bladder cancer (BCa) specimens on clinical outcomes. A systematic review and meta-analysis of the available literature from the past 10 years was performed using MEDLINE, EMBASE and Cochrane library in August 2017. The protocol for this systematic review was registered on PROSPERO (Central Registration Depository: CRD42018084876) and is available in full on the University of York website. Overall, 33 studies (including 6194 patients) evaluating the presence of LVI at TUR were retrieved. LVI was detected in 17.3% of TUR specimens. In 19 studies, including 2941 patients with ≤cT1 stage only, LVI was detected in 15% of specimens. In patients with ≤cT1 stage, LVI at TUR of the bladder tumour (TURBT) was a significant prognostic factor for disease recurrence (pooled hazard ratio [HR] 1.97, 95% CI: 1.47-2.62) and progression (pooled HR 2.95, 95% CI: 2.11-4.13), without heterogeneity (I2 = 0.0%, P = 0.84 and I2 = 0.0%, P = 0.93, respectively). For patients with cT1-2 disease, LVI was significantly associated with upstaging at time of radical cystectomy (pooled odds ratio 2.39, 95% CI: 1.45-3.96), with heterogeneity among studies (I2 = 53.6%, P = 0.044). LVI at TURBT is a robust prognostic factor of disease recurrence and progression in non-muscle invasive BCa. Furthermore, LVI has a strong impact on upstaging in patients with organ-confined disease. The assessment of LVI should be standardized, reported, and considered for inclusion in the TNM classification system, helping clinicians in decision-making and patient counselling.

Department of Special Surgery Jordan University Hospital University of Jordan Amman Jordan

Department of Urology 2nd Faculty of Medicine Hospital Motol Charles University Praha Czech Republic

Department of Urology Careggi Hospital University of Florence Florence Italy

Department of Urology Comprehensive Cancer Centre Medical University of Vienna Vienna Austria

Department of Urology Jikei University School of Medicine Tokyo Japan

Department of Urology Kantonsspital Winterthur Winterthur Switzerland

Department of Urology University of Texas Southwestern Medical Center Dallas TX USA

Department of Urology Weill Cornell Medical College New York NY USA

GRC no 5 ONCOTYPE URO AP HP Hôpital Pitié Salpêtrière Sorbonne Université Paris France

Karl Landsteiner Institute of Urology and Andrology Vienna Austria

Zobrazit více v PubMed

Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin 2018; 68: 7–30 PubMed

Babjuk M, Bohle A, Burger M PubMed

Sylvester RJ, van der Meijden APM, Oosterlinck W PubMed

Mathieu R, Lucca I, Roupret M PubMed

Shariat SF, Karakiewicz PI, Palapattu GS PubMed

Kikuchi E, Margulis V, Karakiewicz PI PubMed PMC

Shariat SF, Svatek RS, Tilki D PubMed

Tilki D, Shariat SF, Lotan Y PubMed

Kim HS, Kim M, Jeong CW PubMed

Go H, Kim P‐J, Jeon YK PubMed

Miyake M, Gotoh D, Shimada K PubMed

Patschan O, Holmang S, Hosseini A PubMed

Weiss BE, Pietzak EJ, Wein AJ PubMed

Fukumoto K, Kikuchi E, Mikami S PubMed PMC

Haas CR, Barlow LJ, Badalato GM PubMed

Li G, Song H, Wang J PubMed PMC

Sha N, Xie L, Chen T PubMed PMC

Ukai R, Hashimoto K, Nakayama H, Iwamoto T. Lymphovascular invasion predicts poor prognosis in high‐grade pT1 bladder cancer patients who underwent transurethral resection in one piece. Jpn J Clin Oncol 2017; 47: 447–52 PubMed

Moher D, Shamseer L, Clarke M PubMed PMC

Liberati A, Altman DG, Tetzlaff J PubMed PMC

Higgins JP. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). Cochrane Collab, 2011.

DerSimonian R, Laird N. Meta‐analysis in clinical trials. Control Clin Trials 1986; 7: 177–88 PubMed

DerSimonian R, Kacker R. Random‐effects model for meta‐analysis of clinical trials: an update. Contemp Clin Trials 2007; 28: 105–14 PubMed

Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta‐analyses. BMJ 2003; 327: 557–60 PubMed PMC

Deeks JJ, Dinnes J, D'Amico R PubMed

Reeves BC, Deeks JJ, Higgins JP, Wells GA. Chapter 13 Including non‐randomised studies, 2011.

Sterne JAC, Hernán MA, Reeves BC PubMed PMC

Andius P, Johansson SL, Holmang S. Prognostic factors in stage T1 bladder cancer: tumor pattern (solid or papillary) and vascular invasion more important than depth of invasion. Urology 2007; 70: 758–62 PubMed

Kassouf W, Spiess PE, Brown GA PubMed PMC

Herr HW. Outcome of patients who refuse cystectomy after receiving neoadjuvant chemotherapy for muscle‐invasive bladder cancer. Eur Urol 2008; 54: 126–32 PubMed

Weizer AZ, Wasco MJ, Wang R PubMed

Cho KS, Seo HK, Joung JY PubMed

Streeper NM, Simons CM, Konety BR PubMed

Seo HK, Cho KS, Chung J PubMed

Font A, Taron M, Gago JL PubMed

Rodriguez Faba O, Palou J, Rosales A PubMed

Badalato GM, Gaya JM, Hruby G PubMed

Green DA, Rink M, Hansen J PubMed

Xie HY, Zhu Y, Yao XD PubMed

Kwon DH, Song PH, Kim HT. Multivariate analysis of the prognostic significance of resection weight after transurethral resection of bladder tumor for non‐muscle‐invasive bladder cancer. Korean J Urol 2012; 53: 457–62 PubMed PMC

Branchereau J, Larue S, Vayleux B PubMed

Brimo F, Wu C, Zeizafoun N PubMed

Bolenz C, Auer M, Strobel P PubMed

Levidou G, Thymara I, Saetta AA PubMed

Olsson H, Hultman P, Rosell J, Jahnson S. Population‐based study on prognostic factors for recurrence and progression in primary stage T1 bladder tumours. Scand J Urol 2013; 47: 188–95 PubMed

Kaimakliotis HZ, Monn MF, Cary KC PubMed

Prelevic R, Stojadinovic M, Simic D PubMed

Svatek RS, Clinton TN, Wilson CA PubMed

Goldsmith B, Baumann BC, He J PubMed

Pietzak EJ, Sterling ME, Smith ZL PubMed

Lucca I, Hofbauer SL, Leitner CV PubMed

Novara G, Matsumoto K, Kassouf W PubMed

Lago‐Hernandez CA, Feldman H, O'Donnell E PubMed PMC

Fernandez‐Gomez J, Solsona E, Unda M PubMed

Xylinas E, Kent M, Kluth L PubMed PMC

Abufaraj M, Shariat SF, Foerster B PubMed

Gakis G, Todenhofer T, Braun M PubMed

Millikan R, Dinney C, Swanson D PubMed

Moschini M, Soria F, Klatte T PubMed

Lapham RL, Grignon D, Ro JY. Pathologic prognostic parameters in bladder urothelial biopsy, transurethral resection, and cystectomy specimens. Semin Diagn Pathol 1997; 14: 109–22 PubMed

Association of patients' sex with treatment outcomes after intravesical bacillus Calmette-Guérin immunotherapy for T1G3/HG bladder cancer

Prognostic value of albumin to globulin ratio in non-muscle-invasive bladder cancer